Filing Flows › Caris Life Sciences (CAI) › Pharma Research and Development Services revenue
Caris Life Sciences (CAI) Pharma Research and Development Services revenue by quarter
Caris Life Sciences' Pharma Research and Development Services revenue was $12.7M in Q3 2026 (third quarter 2026), +10% from Q2 2026. Over the last 6 quarters it ranged from $5.4M (Q1 2026) to $18.5M (Q2 2025).
| Quarter | Pharma Research and Development Services revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $12.7M | +10% | +37% |
| Q2 2026 | $11.5M | +113% | -38% |
| Q1 2026 | $5.4M | -50% | — |
| Q4 2025 | $10.8M | +16% | — |
| Q3 2025 | $9.2M | -50% | — |
| Q2 2025 | $18.5M | — | — |
Q3 2026 at a glance
Caris Life Sciences, Q3 2026: revenue $275M (+27% year over year), operating margin 7.0%, net earnings $15.2M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Caris Life Sciences' Pharma Research and Development Services revenue?
Caris Life Sciences' Pharma Research and Development Services revenue was $12.7M in Q3 2026 (third quarter 2026), +10% from Q2 2026.
How has Caris Life Sciences' Pharma Research and Development Services revenue changed?
Over the last 6 quarters it ranged from $5.4M (Q1 2026) to $18.5M (Q2 2025).